Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
39.8M
-
Shares change
-
-1.93M
-
Total reported value, excl. options
-
$545M
-
Value change
-
+$3.48M
-
Put/Call ratio
-
0.35
-
Number of buys
-
82
-
Number of sells
-
-70
-
Price
-
$13.70
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2025
192 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q2 2025.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.8M shares
of 46.2M outstanding shares and own 86.07% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.54M shares), TORONTO DOMINION BANK (3.19M shares), MORGAN STANLEY (2.48M shares), BlackRock, Inc. (2.41M shares), Jefferies Financial Group Inc. (2.2M shares), Soleus Capital Management, L.P. (2.19M shares), SILVERARC CAPITAL MANAGEMENT, LLC (2.02M shares), ACORN CAPITAL ADVISORS, LLC (1.26M shares), MENORA MIVTACHIM HOLDINGS LTD. (1.15M shares), and SG Americas Securities, LLC (1.15M shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.